California State Teachers Retirement System Has $345,000 Stake in Theravance Biopharma, Inc. (NASDAQ:TBPH)

California State Teachers Retirement System lowered its position in Theravance Biopharma, Inc. (NASDAQ:TBPH) by 17.1% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 38,454 shares of the biopharmaceutical company’s stock after selling 7,930 shares during the period. California State Teachers Retirement System’s holdings in Theravance Biopharma were worth $345,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also modified their holdings of TBPH. Simplicity Solutions LLC acquired a new stake in Theravance Biopharma during the 4th quarter valued at $141,000. Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in shares of Theravance Biopharma by 31.4% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 9,330 shares of the biopharmaceutical company’s stock worth $105,000 after purchasing an additional 2,227 shares during the last quarter. Oasis Management Co Ltd. increased its stake in shares of Theravance Biopharma by 5.6% in the fourth quarter. Oasis Management Co Ltd. now owns 1,006,858 shares of the biopharmaceutical company’s stock valued at $11,317,000 after buying an additional 53,604 shares in the last quarter. Wellington Management Group LLP raised its holdings in shares of Theravance Biopharma by 68.0% in the fourth quarter. Wellington Management Group LLP now owns 287,102 shares of the biopharmaceutical company’s stock valued at $3,227,000 after buying an additional 116,164 shares during the last quarter. Finally, Gerber LLC acquired a new position in Theravance Biopharma during the 4th quarter worth about $112,000. 99.10% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Theravance Biopharma

In other news, SVP Rhonda Farnum sold 4,000 shares of the company’s stock in a transaction dated Wednesday, July 10th. The stock was sold at an average price of $9.00, for a total transaction of $36,000.00. Following the completion of the transaction, the senior vice president now directly owns 335,965 shares of the company’s stock, valued at $3,023,685. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In related news, SVP Rhonda Farnum sold 4,000 shares of Theravance Biopharma stock in a transaction that occurred on Wednesday, July 10th. The stock was sold at an average price of $9.00, for a total value of $36,000.00. Following the sale, the senior vice president now owns 335,965 shares of the company’s stock, valued at approximately $3,023,685. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, major shareholder Eli Samaha bought 999,800 shares of the business’s stock in a transaction on Wednesday, August 7th. The stock was purchased at an average price of $7.80 per share, for a total transaction of $7,798,440.00. Following the purchase, the insider now directly owns 9,511,150 shares in the company, valued at approximately $74,186,970. The disclosure for this purchase can be found here. Company insiders own 6.90% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have weighed in on TBPH shares. HC Wainwright lowered their price objective on shares of Theravance Biopharma from $20.00 to $15.00 and set a “buy” rating for the company in a research report on Tuesday, August 6th. SVB Leerink lowered shares of Theravance Biopharma from an “outperform” rating to a “market perform” rating and lowered their price target for the company from $15.00 to $10.00 in a report on Tuesday, August 6th. StockNews.com downgraded Theravance Biopharma from a “buy” rating to a “hold” rating in a report on Saturday, August 10th. TD Cowen lowered their target price on Theravance Biopharma from $10.00 to $9.00 and set a “hold” rating for the company in a research note on Tuesday, August 6th. Finally, Leerink Partnrs downgraded Theravance Biopharma from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, August 6th. Four research analysts have rated the stock with a hold rating and two have given a buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $13.75.

Theravance Biopharma Trading Down 1.3 %

Shares of TBPH opened at $8.14 on Monday. The stock has a market cap of $398.21 million, a P/E ratio of -9.47 and a beta of 0.24. The stock’s 50-day moving average price is $8.95 and its two-hundred day moving average price is $8.98. Theravance Biopharma, Inc. has a 1 year low of $7.44 and a 1 year high of $11.71.

Theravance Biopharma (NASDAQ:TBPH) last released its quarterly earnings data on Monday, August 5th. The biopharmaceutical company reported ($0.34) earnings per share for the quarter, missing the consensus estimate of ($0.09) by ($0.25). Theravance Biopharma had a negative return on equity of 21.29% and a negative net margin of 73.61%. The firm had revenue of $14.26 million for the quarter, compared to the consensus estimate of $15.81 million. During the same period in the previous year, the business earned ($0.28) EPS. As a group, equities analysts forecast that Theravance Biopharma, Inc. will post -0.97 EPS for the current year.

Theravance Biopharma Profile

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.